NASDAQ:LTRN - Lantern Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 96.08 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$13.77
▼ -0.17 (-1.22%)

This chart shows the closing price for LTRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lantern Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LTRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LTRN

Analyst Price Target is $27.00
▲ +96.08% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lantern Pharma in the last 3 months. The average price target is $27.00, with a high forecast of $29.00 and a low forecast of $25.00. The average price target represents a 96.08% upside from the last price of $13.77.

This chart shows the closing price for LTRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Lantern Pharma.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2021Colliers SecuritiesReiterated RatingBuy$29.00Low
8/18/2020ThinkEquityReiterated RatingBuy ➝ Market Perform$25.00High
8/18/2020Colliers SecuritiesReiterated RatingBuy ➝ Market Perform$24.00High
8/10/2020ThinkEquityInitiated CoverageBuyHigh
7/28/2020Colliers SecuritiesInitiated CoverageBuy$24.00High
(Data available from 7/25/2016 forward)
Lantern Pharma logo
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.
Read More

Today's Range

Now: $13.77
Low: $13.51
High: $14.11

50 Day Range

MA: $14.58
Low: $12.74
High: $16.05

52 Week Range

Now: $13.77
Low: $10.40
High: $24.84

Volume

43,891 shs

Average Volume

60,684 shs

Market Capitalization

$153.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lantern Pharma?

The following Wall Street sell-side analysts have issued reports on Lantern Pharma in the last year: Colliers Securities, and ThinkEquity.
View the latest analyst ratings for LTRN.

What is the current price target for Lantern Pharma?

2 Wall Street analysts have set twelve-month price targets for Lantern Pharma in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 96.1%. Colliers Securities has the highest price target set, predicting LTRN will reach $29.00 in the next twelve months. ThinkEquity has the lowest price target set, forecasting a price of $25.00 for Lantern Pharma in the next year.
View the latest price targets for LTRN.

What is the current consensus analyst rating for Lantern Pharma?

Lantern Pharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LTRN will outperform the market and that investors should add to their positions of Lantern Pharma.
View the latest ratings for LTRN.

What other companies compete with Lantern Pharma?

How do I contact Lantern Pharma's investor relations team?

Lantern Pharma's physical mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The company's listed phone number is 972-277-1136 and its investor relations email address is [email protected] The official website for Lantern Pharma is www.lanternpharma.com.